LWK Stock Overview A biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
eFFECTOR Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for eFFECTOR Therapeutics Historical stock prices Current Share Price US$1.08 52 Week High US$15.88 52 Week Low US$1.06 Beta 0.62 1 Month Change 0% 3 Month Change 0.47% 1 Year Change -90.89% 3 Year Change n/a 5 Year Change n/a Change since IPO -99.71%
Recent News & Updates
eFFECTOR Therapeutics Files Form 15 Jul 31
eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index Jul 04
eFFECTOR Therapeutics Provides Non-Compliance Update Jun 26
eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term Jun 25 eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term
eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities May 18 See more updates
eFFECTOR Therapeutics Files Form 15 Jul 31
eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index Jul 04
eFFECTOR Therapeutics Provides Non-Compliance Update Jun 26
eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term Jun 25 eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term
eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities May 18
New major risk - Revenue and earnings growth May 12 eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. May 10
eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 Apr 28
New major risk - Market cap size Apr 07
eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer Apr 04 eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million. Jan 30
eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million. Jan 25
eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients Dec 08
eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer Nov 29
New major risk - Shareholder dilution Nov 20
Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.23 loss in 3Q 2022) Nov 15
Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml) Oct 25
eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors Sep 12
eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement Aug 06 eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million. Jun 09
eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million. Jun 02
eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million. Jun 01
eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq May 22
eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023 May 13
High number of new directors Apr 21
High number of new directors Feb 17
eFFECTOR Therapeutics, Inc. Provides Positive Clinical Data Update for Zotatifin and General Corporate Update Jan 06
High number of new directors Dec 20
High number of new directors Nov 16
Effector Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19 Oct 27
High number of new directors Oct 10
Effector Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer Sep 27
eFFECTOR Therapeutics, Inc. Doses First Patient in Second Cohort of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19 Sep 15
eFFECTOR Therapeutics Receives A Letter from the Nasdaq Stock Market Staff Sep 02
eFFECTOR Therapeutics Appoints Douglas Warner as Chief Medical Officer Aug 09
eFFECTOR Therapeutics, Inc. Announces Executive Changes Jul 16
Investor sentiment deteriorated over the past week Jul 05
eFFECTOR Therapeutics, Inc. Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity Jun 06
Investor sentiment improved over the past week Jun 03
eFFECTOR Therapeutics, Inc. Announces Interim Data from Its Ongoing Phase 1/2 Clinical Trial of Zotatifin in Solid Tumors May 28
Investor sentiment deteriorated over the past week May 19
High number of new directors May 13
eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 09, 2022 Apr 21
eFFECTOR Therapeutics, Inc. Announces Transition in Clinical Leadership Apr 06
Investor sentiment improved over the past week Mar 23
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
eFFECTOR Therapeutics, Inc. Announces Directorate Changes Feb 17
eFFECTOR Therapeutics, Inc. Provides Pipeline and Business Updates Jan 25
High number of new directors Dec 31
Independent Director recently sold €420k worth of stock Dec 02
Independent Director recently sold €366k worth of stock Nov 27
eFFECTOR Therapeutics, Inc. Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology Nov 25
Independent Director recently sold €362k worth of stock Nov 23
Independent Director recently sold €196k worth of stock Nov 18
Independent Director recently sold €801k worth of stock Nov 13
Third quarter 2021 earnings released: EPS US$0.53 Nov 10 Shareholder Returns LWK DE Biotechs DE Market 7D 0% -1.9% 3.5% 1Y -90.9% -4.2% 13.1%
See full shareholder returns
Return vs Market: LWK underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is LWK's price volatile compared to industry and market? LWK volatility LWK Average Weekly Movement n/a Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: LWK has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LWK's volatility change over the past year.
About the Company eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer.
Show more eFFECTOR Therapeutics, Inc. Fundamentals Summary How do eFFECTOR Therapeutics's earnings and revenue compare to its market cap? LWK fundamental statistics Market cap €182.26k Earnings (TTM ) -€31.02m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LWK income statement (TTM ) Revenue US$0 Cost of Revenue US$21.62m Gross Profit -US$21.62m Other Expenses US$13.02m Earnings -US$34.63m
Last Reported Earnings
Mar 31, 2024
Earnings per share (EPS) -7.36 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 2,420.3%
How did LWK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/09/21 19:33 End of Day Share Price 2024/06/24 00:00 Earnings 2024/03/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources eFFECTOR Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Louise Chen Cantor Fitzgerald & Co. Judah Frommer Credit Suisse Robert Burns H.C. Wainwright & Co.
Show 2 more analysts 